Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,230
Employees2,230
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,230
Employees2,230

ALNY Key Statistics

Market cap
59.63B
Market cap59.63B
Price-Earnings ratio
1.88K
Price-Earnings ratio1.88K
Dividend yield
Dividend yield
Average volume
981.05K
Average volume981.05K
High today
$455.76
High today$455.76
Low today
$444.43
Low today$444.43
Open price
$448.05
Open price$448.05
Volume
559.32K
Volume559.32K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $451.23. The company's market cap stands at 59.63B, with a P/E ratio of 1877.00.

As of 2025-11-30, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $444.43 and $455.76. The current price stands at $451.23, placing the stock +1.5% above today's low and -1.0% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 559.32K, compared to an average daily volume of 981.05K.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

ALNY News

Nasdaq 22h
ALNY Quantitative Stock Analysis

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Mome...

ALNY Quantitative Stock Analysis
Simply Wall St 2d
The Bull Case For Alnylam Pharmaceuticals Could Change Following Raised Sales Guidance for Vutrisiran

Earlier this quarter, Carillon Tower Advisers highlighted Alnylam Pharmaceuticals after the company's launch of vutrisiran for transthyretin amyloidosis surpass...

The Bull Case For Alnylam Pharmaceuticals Could Change Following Raised Sales Guidance for Vutrisiran
Nasdaq 6d
Validea Detailed Fundamental Analysis - ALNY

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Quantitat...

Validea Detailed Fundamental Analysis - ALNY

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More ALNY News

Simply Wall St 6d
Is Alnylam Pharmaceuticals Stock Justified After 73.9% Surge and Clinical Trial Milestones?

Wondering if Alnylam Pharmaceuticals stock offers real value, or if recent momentum has left the price running ahead of its fundamentals? You're definitely not...

Is Alnylam Pharmaceuticals Stock Justified After 73.9% Surge and Clinical Trial Milestones?

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.